Effect of GIP After a Meal in Patients With Type 2 Diabetes
NCT ID: NCT03702660
Last Updated: 2021-04-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
10 participants
INTERVENTIONAL
2017-08-01
2018-01-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes
NCT00732602
GIP/GLP-1 Co-Activity in Subjects With Overweight and Type 2 Diabetes: Lowering of Food Intake
NCT03526289
The Insulin Response to the Gut Hormone GIP After Near-normalisation of Plasma Glucose in Patients With Type 2 Diabetes
NCT04228484
GIP Receptor Antagonist Studies in Humans
NCT02747472
GIP, GLP-1 and GLP-2 in Type 2 Diabetic Hyperglucagonemia
NCT00716170
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GIP(3-30)NH2
GIP receptor antagonist
GIP(3-30)NH2
Peptide derived from the naturally occuring gut hormone GIP
Peripheral venous cannulation
Intravenous access for infusions
Placebo
Placebo (saline infusions)
Peripheral venous cannulation
Intravenous access for infusions
GLP-1
Peripheral venous cannulation
Intravenous access for infusions
GLP-1
Peptide infusion
GLP-1 + GIP(3-30)NH2
GIP(3-30)NH2
Peptide derived from the naturally occuring gut hormone GIP
Peripheral venous cannulation
Intravenous access for infusions
GLP-1
Peptide infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GIP(3-30)NH2
Peptide derived from the naturally occuring gut hormone GIP
Peripheral venous cannulation
Intravenous access for infusions
GLP-1
Peptide infusion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HbA1c \< 75 mmol/mol
* BMI \> 27 kg/m2
* Stable weight (+/- 5%) during the last 3 months
Exclusion Criteria
* More than 14 units of alcohol weekly or abuse of drugs
* Liver disease, estimated at plasma ALAT levels \> 3 x normal value or INR outside normal range
* Reduced kidney function (estimated at eGFR \< 60 ml/min/1,73 m2)
* Severe arteriosclerotic heart disease or heart failure (NYHA III or IV)
* Low red blood cell count (hemoglobin \< 8.3 mmol/l
* Special diet or planned weight change during the trial period
* Any disease/condition, which the clinical investigators assess will disturb the participation in the clinical trial
18 Years
75 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Gentofte, Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Signe Stensen
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Signe Stensen, MD
Role: PRINCIPAL_INVESTIGATOR
Center for Diabetes Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Center for Diabetes Research, Gentofte Hospital
Hellerup, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GA-7
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.